Mini-CHOP and Rituximab in Patients Aged Over 80 Years

Inclusion Criteria: * Patient with histologically proven CD20+ diffuse large B-cell lymphoma (WHO classification). DLBCL with some small cell infiltration in bone marrow or lymph node may be included. * Aged over 80 years. * Ann Arbor stage I bulky, II, III or IV * Age-adjusted International Prognostic Index equal to 0, 1, 2 and 3. * Patient non previously treated. * ECOG performance status ≤ 2. * With a minimum life expectancy of 3 months. * Negative HIV, HBV and HCV serologies test ≤ 4 weeks (except after vaccination). * Having previously signed a written informed consent Exclusion Criteria: * Any other histological type of lymphoma. * Any history of treated or non-treated indolent lymphoma. * Central nervous system or meningeal involvement by lymphoma. * Contra-indication to any drug contained in the chemotherapy regimens. * Any serious active disease (according to the investigator's decision). * Poor renal function (creatinin level\>150µmol/l), poor hepatic function (total bilirubin level\>30mmol/l, transaminases\>2.5 maximum normal level) unless these abnormalities are related to the lymphoma. * Poor bone marrow reserve as defined by neutrophils \<1.5 G/l or platelets \<100 G/l, unless related to bone marrow infiltration. * Any history of cancer during the last 5 years with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma. * Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study. * Adult patient under tutelage.